Health systems across the UK and Europe have been forced into emergency mode after a disruption at a German manufacturing plant between 18th-22nd February 2026, triggered a worldwide shortage of medical bone cement. What initially appeared to be an isolated technical fault has rapidly escalated into a crisis capable of delaying tens of thousands of surgeries. The has event exposed weaknesses in the resilience of global medical supply chains and exposed a reliance on single source suppliers.
The problem began when Heraeus Medical, a German-based healthcare technology firm and one of the world’s leading suppliers of bone cement, announced that it had suffered a critical failure of a packaging machine at its main production site, which compromised sterility assurance and required all newly manufactured cement to be destroyed.
Heraeus has confirmed that all products already on the market are safe to use but given the market dominance and scale of demand, it is unlikely that alternative suppliers will be able to scale production to cover the shortfall in the time scale needed. Consequently, a supply shortage is projected for at least the next two months.
This is not a small disruption. Heraeus supplies approximately 75% of the NHS’s bone cement which is used in 82% of knee replacements and almost 60% of hip replacements, equating to around 15,000 operations every month in England alone. This means that a single production line in one German facility effectively underpins the majority of all cemented joint replacements in the United Kingdom.
The implications of this distribution are immediate: the NHS has ordered hospitals to cancel most elective hip and knee operations and reserve remaining stock for emergency trauma cases. Existing cement already in hospitals is not affected, but even with conservation measures, the available two weeks of supply in the NHS supply chain is insufficient to bridge the projected two‑month production gap.
In the absence of a full report and detailed root‑cause analysis, the available evidence suggests that Heraeus does not possess a fallback packaging capability or third-party arrangement to take over production, revealing what looks like a classic single point of failure.
The crisis also raises significant questions regarding supplier assurance on the part of the health systems that relied on it. For a supplier that provides the majority of bone cement to a G7 country, it is reasonable to ask what business continuity obligations were placed on Heraeus, whether they were required to demonstrate their ongoing preparedness and what resilience planning, supplier monitoring and verification measures the NHS had in place.
This incident demonstrates how the convergence of highly concentrated markets, long production cycle times, strict regulatory standards, and just‑in‑time inventory models can amplify even minor operational failures into systemic disruptions.
There are some initial lessons that can be learned: essential medical supplies should be treated akin to critical national infrastructure, not ordinary procurement items and the importance of supply chain monitoring, alerts and early-warning mechanisms capable of detecting trouble before production is impacted. Ultimately, this highlights the importance of requiring critical suppliers to provide evidence of their resilience arrangements and the importance of validating and testing resilience assumptions through scenario testing high impact disruptions such as supplier failure, product contamination and manufacturing outages